Abstracts tagged "polymyositis/dermatomyositis (PM/DM) and rituximab"

Abstract Number: 211 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Disease Modifying Drugs, Biologic Therapies and Immunoglobulin in Patients with Polymyositis and Dermatomyositis: A Systematic Literature Review
JA Martinez-Lopez Sr.¹, J. Graña Sr.², Santiago Muñoz-Fernandez³, I. Rua-Figueroa⁴, José M. Pego-Reigosa⁵, Estíbaliz Loza Sr.⁶ and SER group for the study of systemic autoimmune diseases⁷, ¹Fundacion Jimenez Diaz, Madrid, Spain, ²Hospital Juan Canalejo, Spain, ³Unit Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ⁴Rheumatology, Hospital de GC Dr Negrin, Las Palmas GC, Spain, ⁵Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ⁶Research Unit. Sociedad Española de Reumatología, Madrid, Spain, ⁷Madrid
Background/Purpose: The aim of this study was to systematically review the efficacy and safety of available drugs in patients with polymyositis (PM) or dermatomyositis (DM)Methods:…
Abstract Number: 220 • 2012 ACR/ARHP Annual Meeting
Efficacy of Rituximab for the Treatment of Refractory Inflammatory Myopathies Associated with Anti-Histidyl-tRNA Synthetase Antibodies (the FORCE Jo1 Study)
Yves Allenbach¹, Aude Rigolet², Marguerite Guiguet³, Isabelle Marie⁴, Eric Hachulla⁵, Dominique Farge⁶, Kuberaka Mariampillai⁷, Serge Jacquot⁸, Fabienne Jouen⁹, Olivier Boyer¹⁰, Lucile Musset¹¹, Serge Herson⁷ and Olivier Benveniste¹², ¹Internal Medicine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France, ²Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ³Biostatistique, Pitie-Salpetriere Hospital, Paris, France, ⁴Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, ⁵Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ⁶Medicine, EBMT, Paris, France, ⁷Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, ⁸INSERM U905, University of Rouen, Rouen, France, ⁹Immunology, Rouen University Hospital, Rouen Cedex, France, ¹⁰Immunology, INSERM U905, University of Rouen, Rouen, France, ¹¹Laboratoire d'Immunochimie, CHU Pitié-Salpêtrière, Paris, France, ¹²Internal Medecine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France
Background/Purpose: anti-histidyl-tRNA synthetase (anti-Jo1) antibodies are found in approximately 25–30% of patients with idiopathic inflammatory myopathies, frequently in the frame of an anti-synthetase syndrome characterized…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].